Case 4: Later Lines of Therapy for Patients With Recurrent HCC
Expert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.
Case 3: Novel Frontline Combination Strategies for Unresectable HCC
Comprehensive insight on several clinical trials analyzing frontline combination therapies for patients with unresectable hepatocellular carcinoma.
Case 3: A 63-Year-Old With Unresectable HCC Eligible for IO Therapy
In the setting of unresectable hepatocellular carcinoma, experts consider the role of frontline atezolizumab + bevacizumab given data from IMbrave150.
Case 2: Treating Child-Pugh B Metastatic Hepatocellular Carcinoma
A brief review of treatment options for patients with Child-Pugh B grade metastatic hepatocellular carcinoma.
Case 2: Adverse Event Management and Dosing of Frontline TKIs
Panelists consider the adverse event profile of frontline TKI therapy in patients with metastatic HCC and review options for dosing and dose reduction.
Case 2: PFS Subgroup Data From the REFLECT Trial in Metastatic HCC
Comprehensive discussion on the PFS subgroup data from REFLECT, which compared frontline lenvatinib and sorafenib therapy in metastatic HCC.
Case 2: Data Supporting Frontline TKI Therapy in Metastatic HCC
Shared insight on clinical trial data in metastatic hepatocellular carcinoma supporting frontline use of sorafenib and lenvatinib, respectively.
Case 2: Selecting Frontline Therapy for Metastatic HCC
Focused discussion on the frontline treatment options available for patients diagnosed with metastatic hepatocellular carcinoma.
Case 2: Role of Biopsy and Imaging in Metastatic HCC
Panelists debate the role of imaging in conjunction with or in place of biopsy in the setting of metastatic hepatocellular carcinoma.
Case 2: A 75-Year-Old With Metastatic HCC
Shifting to a second patient case of metastatic hepatocellular carcinoma, experts consider best diagnostic practices and the initiation of therapy.
Case 1: Systemic Therapy in Combination With or Following TACE/TARE
A brief discussion on the role of systemic therapies in combination with or following TACE/TARE in unresectable hepatocellular carcinoma.
Case 1: Role of TARE in Unresectable Hepatocellular Carcinoma
Expert perspectives on the role of transarterial radioembolization in unresectable hepatocellular carcinoma following FDA approval.
Case 1: A 60-Year-Old With Unresectable Hepatocellular Carcinoma
Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.
